MRD as an endpoint in clinical trials
Peter Hillman, MD, ChB, from Leeds Teaching Hospital NHS Trust, Leeds, UK, provides an insight into the use of measurable residual disease (MRD) as an endpoint in clinical trials. MRD allows for compa...
Author: VJHemOnc
Added: 06/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Clinical Trials | Hospitals | Teaching | Teaching Hospitals | Universities & Medical Training